Phenytoin at optimum doses ameliorates experimental autoimmune encephalomyelitis via modulation of immunoregulatory cells

Journal of Neuroimmunology

Volumn 233, Issue 1-2, 2011, Pages 112-119

  Hashiba, Naomi ^a   Nagayama, Shigemi ^a   Araya, Shin ich ^a   Inada, Hiroyuki ^a   Sonobe, Yoshifumi ^a   Suzumura, Akio ^b   Matsui, Makoto ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

CD127; CD8; EAE; Phenytoin; Regulatory T cells

Indexed keywords

INTERLEUKIN 7 RECEPTOR; PHENYTOIN; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; PHENYTOIN; T-LYMPHOCYTES, REGULATORY;

EID: 79953319174     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.12.006     Document Type: Article

References (43)

1. Andrade-Mena C.E., Sardo-Olmedo J.A.J., Ramirez-Lizardo E.J. Effects of phenytoin administration on murine immune function. J. Neuroimmunol. 1994, 50:3-7.
2. Astier A.L., Meiffren G., Freeman S., Hafler D.A. Alterrations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006, 116:3252-3257.
3. + regulatory T cells. Trends Immunol. 2006, 27:541-544.
4. Bjartmar C., Wujek J.R., Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 2003, 206:165-171.
5. Black J.A., Waxman S.G. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J. Neurol. Sci. 2008, 274:57-63.
6. Black J.A., Liu S., Hains B.C., Saab C.Y., Waxman S.G. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 2006, 129:3196-3208.
7. Black J.A., Liu S., Carrithers M., Carrithers L.M., Waxman S.G. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann. Neurol. 2007, 62:21-33.
8. Black J.A., Liu S., Waxman S.G. Sodium channel activity modulates multiple functions in microglia. Glia 2009, 57:1072-1081.
9. Carrithers M.D., Dib-Hajj S., Carrithers L.M., Tokmoulina G., Pypaert M., Jonas E.A., Waxman S.G. Expression of the voltage-gated sodium channel NaV1.5 in the macrophage late endosome regulates endosomal acidification. J. Immunol. 2007, 178:7822-7832.
10. Chow S.A., Fischer L.J. Phenytoin metabolism in mice. Drug Metab. Dispos. 1982, 10:156-160.
11. Costantino C.M., Baecher-Allan C., Hafler D.A. Multiple sclerosis and regulatory T cells. J. Clin. Immunol. 2008, 28:697-706.
12. Craner M.J., Damarjian T.G., Liu S., Hains B.C., Lo A.C., Black J.A., Newcombe J., Cuzner M.L., Waxman S.G. Sodium channels contibute to microglia/macrophage activation and function in EAE and MS. Glia 2005, 49:220-229.
13. + regulatory T-cell function: an ex vivo and in vivo longitudinal study in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 2007, 182:204-211.
14. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., Ferrero B., Eid P., Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann. Neurol. 2009, 65:499-509.
15. Fox N.C., Jenkins R., Leary S.M., Stevenson V.L., Losseff N.A., Crum W.R., Harvey R.J., Rossor M.N., Miller D.H., Thompson A.J. Progressive cerebral atrophy in MS. A serial study using registered, volumetric MRI. Neurology 2000, 54:807-812.
16. + channel activity. FEBS Lett. 2004, 569:191-194.
17. Huehn J., Polansky K.J., Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nat. Rev. Immunol. 2009, 9:83-89.
18. + T cells in murine experimental allergic encephalomyelitis. Science 1992, 256:1213-1215.
19. + influx in human T cells: role in T cell activation. J. Neuroimmunol. 1999, 99:53-60.
20. Kikuchi K., McCormick C.I., Neuwelt E.A. Immunodsuppression by phenytoin: implication for altered immune competence in brain-tumor patients. J. Neurosurg. 1984, 61:1085-1090.
21. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169:4712-4716.
22. + regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. J. Neuroimmunol. 2007, 191:51-60.
23. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., Bäckström B.T., Sobel R.A., Wucherpfennig K.W., Strom T.B., Oukka M., Kuchroo V.K. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 2007, 13:423-431.
24. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002, 125:2202-2212.
25. + T reg cells. J. Exp. Med. 2006, 203:1701-1711.
26. Lo A.C., Black J.A., Waxman S.G. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. NeuroReport 2002, 13:1909-1912.
27. Lo A.C., Saab C.Y., Black J.A., Waxman S.G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol. 2003, 90:3566-3571.
28. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8:913-919.
29. + regulatory cells within the central nervous system. J. Immunol. 2005, 175:3025-3032.
30. + regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J. Neuroimmunol. 2010, 218:120-124.
31. O'Connor R.A., Leech M.D., Suffner J., Hämmerling G.J., Anderton S.M. Myelin-reactive, TGF-β-induced regulatory T cells can be programmed to develop Th1-like effector function but remain less proinflammatory than myelin-reactive Th1 effectors and can suppress pathogenic T cell clonal expansion in vivo. J. Immunol. 2010, 185:7235-7243.
32. + channel β2 subunits is neuroprotective in a mouse model of multiple sclerosis. Mol. Cell. Neurosci. 2009, 40:143-155.
33. Sriram S., Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 2005, 58:939-945.
34. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
35. bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol. 2009, 215:125-128.
36. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
37. von Boehmer H. Mechanism of suppression by suppressor T cells. Nat. Immunol. 2005, 6:338-344.
38. Waxman S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat. Clin. Prac. Neurol. 2008, 4:159-169.
39. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
40. Wiendl H., Hohlfeld R. Multiple sclerosis therapeutics. Unexpected outcomes clouding undisputed success. Neurology 2009, 72:1008-1015.
41. Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action. Neurology 1998, 51:682-689.
42. Zozulya A.L., Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat. Clin. Pract. Neurol. 2008, 4:384-398.
43. Zsiros E., Kis-Toth K., Hajdu P., Gaspar R., Bielanska J., Felipe A., Rajnavolgyi E., Panyi G. Developmental switch of the expression of ion channels in human dendritic cells. J. Immunol. 2009, 183:4483-4492.